Pharmaceutical company AcuCort will attend the BIO International Convention, 22-25 June 2026 in San Diego, USA. The participation comes at a strategically important juncture, following the company's recent agreement with the FDA as it actively prepares its New Drug Application (NDA) submission.
In April 2026, AcuCort announced that it had reached an agreement with the FDA regarding its Initial Pediatric Study Plan (iPSP) for Zeqmelit®. The agreement represents a significant regulatory milestone and a prerequisite for the NDA submission in the United States that the company plans to file during 2026.
- The FDA agreement is a concrete step towards the US market and creates a strong foundation for the partnering discussions we are now conducting. We are seeing a clear and growing interest in AcuCort from potential international partners, says Jonas Jönmark, CEO of AcuCort.
In January, AcuCort entered into a commercial agreement with Glenmark Pharmaceuticals for six European markets, and preparations for registration under the Repeat Use Procedure (RUP) are currently under way.
AcuCort's CEO Jonas Jönmark and Business Development Director Anna Chérouvrier Hansson will attend the BIO International Convention, where AcuCort will be represented in the Swedish pavilion in the exhibition area (alongside other innovative companies).
Meetings with AcuCort can be booked via the BIO Partnering™ platform or by contacting Anna Chérouvrier Hansson (anna.hansson@acucort.com).
About BIO International Convention
The BIO International Convention is one of the world's largest and most comprehensive gatherings for biotechnology, bringing together the entire industry - from research and development to industry and investment - with approximately 20,000 leading figures from around the world. Read more: https://convention.bio.org
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.